QFW
NBIX icon

QTR Family Wealth’s Neurocrine Biosciences NBIX Stock Holding History

QTR Family Wealth’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$278K Sell
1,649
-205
-11% -$30.4K 0.1% 236
2026
Q1 		$243K Sell
1,854
-413
-18% -$54.8K 0.1% 240
2025
Q4 		$312K Buy
2,267
+818
+56% +$119K 0.14% 173
2025
Q3 		$203K Buy
+1,449
New +$196K 0.1% 244

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

QTR Family Wealth's NBIX Position: Q2 2026 in Review

QTR Family Wealth reduced its Neurocrine Biosciences (NBIX) stake by 11% in Q2 2026, selling an estimated $30.4K and leaving 1,649 shares worth $278K. The position accounts for 0.1% of the portfolio, ranked #236.

QTR Family Wealth first reported a position in NBIX in Q3 2025 and has held it in 4 quarters since. The position peaked at $312K in Q4 2025. 411 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • QTR Family Wealth held 1,649 shares of Neurocrine Biosciences worth $278K as of Q2 2026.
  • QTR Family Wealth sold 205 Neurocrine Biosciences shares in Q2 2026, an estimated $30.4K.
  • Neurocrine Biosciences made up 0.1% of QTR Family Wealth's portfolio in Q2 2026, its #236 holding.
  • QTR Family Wealth first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 4 quarters since.
  • QTR Family Wealth's Neurocrine Biosciences position peaked at $312K in Q4 2025.
  • 411 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on QTR Family Wealth's 13F filing for Q2 2026, filed 27 Jul 2026.